1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Obesity Firm Allurion Preps For Global Expansion, US Trial With Changes At Top

Intragastric balloon-maker Allurion is making some major changes in its executive suite to support its plan to expand its market reach.

Allurion Technologies Inc. is ramping up its leadership team, supporting efforts to enter new markets with its Elipse Balloon, a nonsurgical gastric balloon intended to treat patients with obesity. The device was CE-marked in 2015 and is available in 10 countries in Europe and the Middle East, but the company says it is gearing up with the help of new funds to start a US FDA pivotal and expand its commercial presence.

The firm said on Jan. 2 that Shantanu Gaur, a cofounder of Allurion, took on the role of CEO at the start of the new year, while Jonathan Wecker, who had been CEO since 2010, moved to the posts of chairman and chief operating officer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

No Knife, No Burn, Just Bubbles: HistoSonics Hits 90% Tumor Control In #HOPE4Liver Trial, Eyes IPO Timing

 
• By Marion Webb

HistoSonics, which developed a noninvasive technology to destroy tumor cells, reports 90% local tumor control at 12-month follow-up in the #HOPE4Liver Trial. The Edison System, cleared by the US FDA in late 2023, is also being evaluated for kidney and pancreatic tumors. CEO Mike Blue said the medtech is financially secure but watching public markets as it considers an IPO.

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 
• By Brian Bossetta

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.

First Liver Cancer Surveillance Test In Five Years Receives FDA Breakthrough Status

 
• By Natasha Barrow

Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.